Acurx Pharmaceuticals (ACXP) Price to Book (2021 - 2026)

Acurx Pharmaceuticals (ACXP) has reported Price to Book for 6 consecutive years, with 0.89 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 73.88% year-over-year to 0.89; the trailing twelve-month figure through Jun 2026 stood at 0.89 (down 73.88% YoY), and the FY2025 full-year result was 0.71, down 96.86% from the prior year.
• Price to Book declined to 0.89 in Q2 2026 per ACXP's latest filing, from 1.44 in the prior quarter.
• Across five years, Price to Book topped out at 22.54 in Q4 2024 and bottomed at 0.71 in Q4 2025.
• Historically, Price to Book has averaged 6.18 across 5 years, with a median of 4.69 in 2023.
• The sharpest annual moves came in 2023 and 2025: Price to Book soared 141.43% in 2023, then tumbled 96.86% in 2025.
• Over 5 years, Price to Book stood at 6.33 in 2022, then surged by 87.69% to 11.87 in 2023, then soared by 89.8% to 22.54 in 2024, then sank by 96.86% to 0.71 in 2025, then increased by 25.71% to 0.89 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 0.89, 1.44, and 0.71 for Q2 2026, Q1 2026, and Q4 2025 respectively.